Showcasing Excellence: 2025 CSGCT Conference Project Roadshow Now Open for Submissions
In March this year, AstraZeneca, one of the international pharmaceutical giants, announced the acquisition of all issued equity interests in EsoBiotec, an in vivo cell therapy company, for a total consideration of up to $1 billion. This move marks another strategic advance by AstraZeneca in the cell therapy market, following its prior acquisitions of two other cell therapy companies, TeneoTwo and Gracell.
On June 30, AbbVie, a leader in the field of autoimmune diseases, announced its acquisition of Capstan Therapeutics for $2.1 billion. Capstan was founded by Carl June and Bruce Levine, renowned pioneers in CAR-T therapy, along with Drew Weissman, the 2023 Nobel Laureate in Physiology or Medicine and a foundational figure in mRNA technology. This deal adds another significant milestone to business development transactions in the CGT sector in 2025.
In terms of product commercialization, Legend Biotech’s independently developed CAR-T product, ciltacabtagene autoleucel (CARVYKTI®) became the first domestically produced CGT product to receive approval from the U.S. FDA, with sales reaching $963 million in 2024 and further hitting $808 million in the first half of 2025, fully demonstrating its international competitiveness.
Industry investors have stated, “The CGT sector has reached a turning point for bottoming out and rebounding; it is time to extend greater patience and confidence to CGT. Each technological pathway within CGT possesses its own intrinsic logic and development prospects. Although the maturation pace varies across different routes, all invariably require continuous exploration and long-term technical commitment from the industry. Amid the current industry cycle fraught with uncertainties, investors and developers should focus more on projects with a solid scientific foundation, advancing clinical validation in a steady and pragmatic manner.” As a frontier track in the biopharmaceutical field, CGT is gradually becoming a core growth driver for the global healthcare industry, leveraging its disruptive therapeutic potential.
However, the logic that “good things are worth waiting for” may no longer hold in today’s hyper-competitive landscape, characterized by severe product homogenization and a surge in business development (BD) transactions within the biopharmaceutical sector. Proactively highlighting project strengths to ensure high-quality assets gain visibility, thereby fostering a mutually beneficial match between talent and opportunity, is the effective path toward achieving genuine win-win cooperation.
Standing at the threshold of a new era of revolutionary change, and facing the surging dynamics of frontier and high-profile sectors, enterprises and venture capital firms need to achieve deeper integration and mutual engagement. This is essential to accelerate the translation of results and commercialization of high-quality CGT projects both in China and globally., 2025 The 2nd China Cell and Gene Therapy (CSGCT) CongressSpecially Curated“2025 CSGCT Conference Project Roadshow”This session showcases the industrialization achievements of innovation and entrepreneurship projects, facilitates in-depth exchanges between investment institutions and enterprises, supports the full-chain commercial development of companies in the cell and gene therapy (CGT) sector, and builds a distinctive industrial ecosystem tailored to CGT.
Over the past decade, VCBeat, one of the organizers of roadshows, has hosted nearly 100 series of investment and financing forums, including pitch events, BD salons, and technology transaction conferences. These events have focused on cutting-edge applied research, the commercialization of scientific achievements, and product collaboration models, covering more than 80% of the rich investment and financing resources in the pharmaceutical industry, such as USD funds, RMB funds, innovative enterprises, and industrial investors.
The project roadshow session at the 2025 CSGCT Conference will leverage VCBeat’s extensive investment, financing, and business development (BD) resources to create abundant collaboration and communication opportunities for exhibiting companies, build an efficient matchmaking platform, and gather1,000+ Leading Investment Institutions, Industrial Investors, and Government Industrial Guidance Fund Decision-Makers from China and Abroad, attracting multinational corporations (MNCs) and renowned domestic and international medical and pharmaceutical companies seeking business development (BD) collaborations on high-quality projects, product candidates, and technologies, thereby accelerating the exchange and cooperation on the most distinctive new technologies, new products, and new ecosystems in China’s cell and gene therapy (CGT) sector.
01.
Mentors for Project Pitch Sessions
This project roadshow session brings togetherMNC, large pharmaceutical companies' business development teams, investment institutions, government industrial parks, and client pharmaceutical companiesUpon the arrival of representatives, a four-dimensional matchmaking platform integrating “technology, capital, scenarios, and policy” will be jointly established. Through three key segments—project roadshows, one-on-one private negotiations, and green channels for park-based implementation—cutting-edge gene editing projects will engage directly with industry stakeholders to spark immediate collaboration, thereby accelerating the entire continuum from laboratory research to clinical application, and from financing to commercial deployment.
Proposed Invited Attending Institutions
Swipe left or right to view more, click to enlarge (listed in no particular order)
02.
Roadshow Section
This roadshow session coversCGT Sector: Assets, Commercialization of Research Achievements, and Supply Chain Enterprisesthree major content sections, at which time there will beDomestic and international CGT innovative biotech companies, MNCs, business development teams at large pharmaceutical companies, investment institutions, decision-makers at government industrial guidance funds, industry investors, VCs, and FAsWith key players from the global CGT industry chain in attendance, the roadshow will comprehensively showcase the core advantages, technical highlights, market prospects, and business models of the participating projects to over 1,000 investors and corporate client representatives. By leveraging innovative approaches and efficient mechanisms, the event aims to achieve superior matching between high-quality assets and core buyers.
■ Asset Roadshow
The Asset Roadshow section focuses on core assets of projects in the cell and gene therapy (CGT) field, including but not limited to patented technologies and platforms, R&D achievements, product pipelines, and product services. By providing a detailed presentation of the unique advantages of these core assets, it aims to attract the attention of investors and partners, thereby offering strong support for project financing, technology transfer, and collaborative development.
Type of Applicant Organization: Innovative CGT Pharmaceutical Company
Mentor Type: Business Development (BD) at MNCs and Large Pharmaceutical Companies,VC/PE/CVC, Government Industrial Parks, Clinical PIs
■ Roadshow for the Commercialization of Scientific Research Achievements
The CGT Project Commercialization Roadshow focuses on the translational capacity of cell and gene therapy (CGT) projects, showcasing the complete pathway from laboratory research to clinical application and market entry. It highlights key aspects such as the R&D team, technology maturity, commercialization potential, and business model, aiming to attract pharmaceutical companies, government industrial parks, and investment institutions seeking high-quality projects. This initiative fosters deep integration between projects and the industry, accelerating the industrialization of scientific achievements.
Applicant Unit Type: Hospitals/PIs, universities, research institutions, scientific teams, etc.
Mentor Type: Party A (pharmaceutical companies), government industrial parks, VC/CVC, MNCs, and large pharmaceutical companies’ BD departments
■ Supply Chain Enterprise Roadshow
Supply Chain Enterprise Roadshow aims to showcase the positioning and advantages of corporate projects within the Cell and Gene Therapy (CGT) industry chain, including enterprises that provide various product and service support for CGT product research and development, manufacturing, transportation, and usage. By optimizing supply chain management, it reduces costs, improves efficiency, and enhances the market competitiveness of projects. Meanwhile, it also provides opportunities for projects to establish cooperative relationships with upstream and downstream enterprises.
Applicant Type: Supply chain enterprises providing products and services in the CGT sector
Supervisor Type: Party A (pharmaceutical companies), VC/PE/CVC, government industrial parks
03.
Project Area
This roadshow is primarily seeking innovative projects in the following CGT fields:
● Gene Therapy
Gene therapy technologies, products, patents, R&D platforms, research findings, or project progress, etc.
● Nucleic Acid Drugs
Nucleotide-based therapeutics developed from DNA, RNA, or synthetic oligonucleotide analogs
● Gene Editing
Products, patents, platforms, research findings, or project progress based on gene editing technology
● Immune Cell Therapy
Therapeutic products, technical patents, technology platforms, research findings, or project progress based on immune cell development, etc.
● Stem Cell Therapy
Therapeutic products, technical patents, technology platforms, research findings, or project progress developed based on stem cells
● Supply Chain Products
Various products and services that support the research and development, manufacturing, transportation, and use of CGT products
04.
Project Solicitation Requirements
● Innovativeness: The project features breakthrough technologies or disruptive therapeutic effects, capable of addressing the limitations of existing treatments or meeting unmet medical needs. Its supply chain products offer high cost-effectiveness and innovative manufacturing processes, which can enhance the standardization, robustness, scalability, and reproducibility of production workflows while reducing costs.
● Conversion Potential: The project features a clear business plan and market positioning, demonstrating strong growth potential and profitability.
● Team Strength: The project team possesses extensive industry experience and professional expertise, ensuring the smooth implementation of the project.
● Business Model: The project features a mature business model and a clear business plan.
● Intellectual Property: Clear project intellectual property rights, free from legal disputes
05.
Project Benefits
● Exhibition Opportunities: Showcase the latest products/solutions/technologies to 1,000+ professional attendees in the cell and gene therapy industry
● Partnership Opportunities: Engage directly with top-tier investors, corporate executives, scientists, and seasoned business development professionals to access industry resource matchmaking.
● Financing Opportunities: Face numerous renowned investment institutions and secure financing opportunities ranging from tens of millions to hundreds of millions.
● Publicity and Exposure: Backed by top-tier industry media coverage to enhance project visibility and influence
● Policy Support: Priority access to policy support, including government industrial funds, science and technology project applications, and tax incentives
● Professional Services: Enjoy professional services including project coaching, business planning, and market promotion to accelerate project growth.
● Direct Access to ASGCT: We will select top cases from outstanding projects and prioritize their submission to the 2026 ASGCT Annual Meeting.
06.
Project Roadshow Registration
2025 CSGCT Conference Project Roadshow: Now Open for Submissions
